PMV Pharmaceuticals, Inc. (PMVP) Investor Relations Documents

PMV Pharmaceuticals, Inc. (PMVP) investor relations documents from the company's IR site: 2 presentations, 34 press releases; latest deck 2026-05-19. Read in-app with summaries. First-party data.

Corporate Presentation - May 2026: PMV Pharmaceuticals is developing rezatapopt, a first-in-class p53 Y220C reactivator, with an NDA submission planned for 1Q2027 in platinum-resistant ovarian cancer.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14Press releasePMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-05-19PresentationCorporate Presentation - May 2026
2026-05-12Press releasePMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-04-22Press releasePMV Pharmaceuticals Announces Board Chair Transition
2026-03-06Press releasePMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
2026-02-26Press releaseNew England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in
2025-11-12Press releasePMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
2025-10-24Press releasePMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Mul
2025-10-13Press releasePMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025
2025-09-10PresentationPYNNACLE Phase 2 Clinical Update Investor Webinar
2025-09-10Press releasePMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple
2025-08-07Press releasePMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
2025-05-23Press releasePMV Pharmaceuticals to Participate at Upcoming Investor Conferences
2025-03-03Press releasePMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
2025-02-11Press releasePMV Pharmaceuticals to Participate at Upcoming Investor Conferences
2024-11-07Press releasePMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
2024-10-23Press releasePMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
2024-09-20ESG reportESG
2024-08-08Press releasePMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Tr
2024-05-30Press releasePMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
2024-05-29Press releaseFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Cla
2024-05-09Press releasePMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
2024-03-27Press releasePMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53
2024-03-18Press releasePMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presen
2024-02-29Press releasePMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
2023-11-09Press releasePMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
2023-08-09Press releasePMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
2023-05-10Press releasePMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
2023-03-01Press releasePMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
2022-08-09Press releasePMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
2022-05-10Press releasePMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
2022-03-01Press releasePMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
2021-11-12Press releasePMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
2021-08-13Press releasePMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
2021-05-14Press releasePMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
2021-03-03Press releasePMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
2020-11-13Press releasePMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

PMVP overview · PMVP earnings · PMVP financials · PMVP KPIs · PMVP ownership · PMVP peers · PMVP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.